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Breast cancer is an important public health
problem worldwide. In the United States,
breast cancer represents the most common
neoplasm and the second most frequent cause
of cancer death in women (American Cancer
Society 2006). Steroidal estrogens have been
implicated in the etiology of breast cancer and
have been added to the list of known human
carcinogens [International Agency for Research
on Cancer (IARC) 1999, 1987; National
Toxicology Program (NTP) 2002]. Estrogens
are suggested to cause breast cancer by stimu-
lating cell growth and proliferation through
receptor-mediated processes and via their
genotoxic metabolites (Cavalieri et al. 2006;
Yager and Davidson 2006). Phytoestrogens are
a class of plant-derived compounds that are
structurally similar to mammalian estrogens
(Sirtori et al. 2005). Ecologic observations
indicate that the incidence of breast cancer is
much lower in Asian women, who consume
signiﬁcantly higher amounts of phytoestrogens
than Western women (Adlercreutz 2002).
Second- and third-generation descendants of
women who migrated to Western countries
from Asia have breast cancer risks similar to
those of women in the host country, suggest-
ing that lifestyle and not genetic factors explain
the low breast cancer risk observed in Asian
women (Probst-Hensch et al. 2000; Usui
2006). However, despite recent attention
related to the putative chemoprotective prop-
erties of phytoestrogens, epidemiologic studies
have produced inconsistent results, and the
relationship between phytoestrogens and breast
cancer remains enigmatic (Gikas and Mokbel
2005; Messina et al. 2006; Peeters et al. 2003;
Trock et al. 2006). Moreover, the possible
mechanisms of phytoestrogen action in breast
cancer have yet to be resolved.
Phytoestrogen Classiﬁcation
Phytoestrogens are biologically active phenolic
compounds of plant origin that structurally
mimic the principal mammalian estrogen
17β-estradiol (E2; Figure 1) (Sirtori et al.
2005). Shared structures include a pair of
hydroxyl groups and a phenolic ring, which is
required for binding to estrogen receptors
(ER)-α and ER-β, and the position of these
hydroxyl groups appears to be an important
factor in determining their abilities to bind
the ERs and activate transcription (Le Bail
et al. 2000). Four main classes of compounds
are currently recognized as phytoestrogens—
the isoﬂavones, stilbenes, coumestans, and lig-
nans (Moon et al. 2006; Sirtori et al. 2005).
These types of phytochemicals are some of the
most prevalent compounds found in fruits,
vegetables, legumes, and tea and are generally
concentrated in the fruit skin, bark, and ﬂow-
ers of plants (Moon et al. 2006). Resveratrol,
daidzein, quercetin, and genistein represent
four of the most commonly ingested and most
intensely studied phytoestrogens (Figure 1).
In East and Southeast Asia, the average
daily intake of phytoestrogens is estimated to
be between 20 and 50 mg (Adlercreutz 1998;
Sirtori et al. 2005). In contrast, the typical diet
of an adult in the United States contains only
0.15–3 mg phytoestrogens per day, and in
Europe the average daily phytoestrogen con-
sumption is estimated to be even lower, falling
between 0.49 and 1 mg (Adlercreutz 1998;
Sirtori et al. 2005). According to various epi-
demiologic studies, plasma isoﬂavone concen-
trations range from 2 μM (Japanese men) to
5 nM (Finnish study subjects); however, local
tissue phytoestrogen concentrations are sug-
gested to be 2–3 times higher than plasma lev-
els (Adlercreutz et al. 1993; Arai et al. 2000;
Morton et al. 2002; Uehar et al. 2000).
Phytoestrogens and Breast
Cancer Risk
The importance of estrogens in the etiology of
breast cancer is widely recognized (Bhat et al.
2003; Cavalieri et al. 2006; Yager and
Davidson 2006). Estrogens have been impli-
cated in the initiation and promotion stages of
breast cancer, and lifetime estrogen exposure
is a major risk factor for breast cancer develop-
ment (Yager and Davidson 2006). Estrogens
exert their carcinogenic effects via ER-depen-
dent mechanisms as well as their genotoxic
metabolites (Bhat et al. 2003; Cavalieri et al.
2006; Yager and Davidson 2006).
Epidemiologic evidence suggests that diet
and nutrition can influence cancer develop-
ment, and women living in Asia, where diets
have traditionally included soybean products,
report fewer postmenopausal symptoms and
experience fewer breast cancers than women
in Western countries (Adlercreutz 2002;
Nichenametla et al. 2006; Usui 2006). More
speciﬁcally, Asian women have a 3-fold lower
breast cancer risk than women in the United
States, independent of body weight (Ursin
et al. 1994). Furthermore, serum concentra-
tions of E2 are 40% lower in Asian women
compared with their Caucasian counterparts
(Peeters et al. 2003). Thus, environmental
and dietary factors may explain at least some
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between populations (Adlercreutz 2002;
Nichenametla et al. 2006). The assertion that
dietary and lifestyle factors may be partially
responsible for the low breast cancer risks
detected in Asian women is supported by
observations in Asian women who immigrate
to Western countries. The second- and third-
generation descendants of women who
migrated from Asia to Western countries have
breast cancer risks similar to those of women
in the host country, suggesting that lifestyle
and not genetic factors explain the low breast
cancer risk of women in Asia (Probst-Hensch
et al. 2000; Usui 2006).
Phytoestrogens exhibit a wide array of
pharmacologic properties, and recently, inter-
est in the potential benefits of diets high in
phytoestrogens has intensiﬁed, especially those
related to chemoprevention. The link between
phytoestrogens and breast cancer prevention
has been the subject of numerous studies, and
the epidemiology of breast cancer in relation to
phytoestrogen consumption has recently been
extensively reviewed (Adlercreutz 2002;
Messina et al. 2006; Ziegler 2004). Generally,
epidemiologic studies have been inconclusive,
and the relationship between phytoestrogens
and breast cancer prevention remains uncertain
(Messina et al. 2006; Trock et al. 2006; Ziegler
2004). Some studies have revealed the modest
protective effects of phytoestrogens; others
have detected no association between phyto-
estrogen intake and breast cancer risk; and a
few have reported marked protective effects
(Hirohata et al. 1985; Hirose et al. 1995; Key
et al. 1999; Nomura et al. 1978, 1985; Trock
et al. 2006; Wu et al. 1996; Yuan et al. 1995).
A recent review of 21 case–control and 15
prospective studies concluded that there is no
clear evidence that phytoestrogen intake inﬂu-
ences the risk of developing breast cancer
(Gikas and Mokbel 2005). Nevertheless, some
evidence suggests that soy intake must be high
during certain windows of development,
speciﬁcally prepubescence, in order to gain the
protective effect of phytoestrogens (Hirayama
1990a, 1990b; Key et al. 1999; Lamartiniere
2000; Shu et al. 2001; Wakai et al. 1999; Wu
et al. 1996). Despite intense investigation, it
remains unclear whether phytoestrogens are
actually chemoprotective agents or whether
their presence is simply a biomarker indicative
of a healthy diet.
Phytoestrogens and Estrogen
Biosynthesis
Various dietary intervention studies in
humans have examined the effects of phyto-
estrogens on estrogen biosynthesis and estro-
gen biosynthetic enzymes. Neither a 2-year
study in which 220 premenopausal women
consumed 100 mg isoflavones per day nor a
short-term study in which premenopausal
women consumed 38 mg isoﬂavones per day
revealed significant alterations in steroid
hormone levels or menstrual cycle length
(Hargreaves et al. 1999; Maskarinec et al.
2002). In contrast, other researchers have
reported decreased plasma concentrations of
follicle-stimulating hormone (FSH), luteiniz-
ing hormone (LH), E2, and progesterone as
well as decreased serum concentrations of E2
and estrone following increased phytoestrogen
consumption (Duncan et al. 1999; Kumar
et al. 2002; Lu et al. 2000a; Nagata et al.
1998). Another study, which evaluated pre-
menopausal women after consumption of
isoﬂavone-supplemented diets for three men-
strual cycles, reported that isoflavone intake
decreased urinary excretion of E2, estrone,
estriol, and total estrogens (Xu et al. 1998).
Moreover, the isoflavone diet increased the
ratio of 2-hydroxyestrone to 16α-hydroxy-
estrone and decreased in the ratio of genotoxic
estrogens to total estrogens (Xu et al. 1998). A
separate study identiﬁed a 27% increase in the
ratio of 2-hydroxyestrone to 16α-hydroxy-
estrone in women given an isoﬂavone-rich diet
compared with women on an isoﬂavone-free
diet (Lu et al. 2000b). Furthermore, in
women consuming 40 mg isoflavones each
day for 3 months, the average menstrual cycle
length was increased 3.52 days, and the follic-
ular phase of the cycle was increased 1.46 days
on average (Kumar et al. 2002). The implica-
tion of increased menstrual cycle length is a
decrease in the total lifetime number of cycles,
thereby minimizing the exposure of breast
epithelial cells to estrogens.
The decrease in circulating estrogen con-
centrations after phytoestrogen consumption
may be a result of interference with estrogen
biosynthetic enzymes, namely cytochrome
P450 19 aromatase (Cyp19) and 17β-hydroxy-
steroid dehydrogenase (HSD) (Rice and
Whitehead 2006). Cyp19 catalyzes the con-
version of androstenedione and testosterone to
estrone (E1) and E2, respectively (Thompson
and Siiteri 1974). HSD catalyzes the inter-
conversion of the relatively inactive 17β-keto
steroids, such as estrone and androstenedione,
to active 17β-hydroxyl steroids such as E2 and
testosterone (Gunnarsson et al. 2003). In the
breast tissue of postmenopausal women, HSD
and Cyp19 are responsible for the local pro-
duction of estrogens, and overexpression or
increased activity of these enzymes is associ-
ated with breast cancer (Li et al. 1998;
Pasqualini et al. 1996; Yue et al. 2001).
Among the phytoestrogens, ﬂavones, and
flavonones are the most potent inhibitors of
Cyp19 aromatase, whereas the isoﬂavones are
relatively weaker aromatase inhibitors. Several
phytoestrogens, including 7-hydroxyflavone,
apigenin, chrysin, and hesperetin were found
to be effective aromatase inhibitors in human
placental microsomes, with IC50 (concentra-
tion of phytoestrogens that reduces enzyme
activity by 50%) values ranging from 0.3 to
3.0 μM (Jeong et al. 1999; Le Bail et al.
2000). In H295R human adrenocortical car-
cinoma cells, both flavones and flavonones
exerted inhibitory effects on aromatase
(Sanderson et al. 2004). Similarly, quercetin,
genistein, and daidzein suppressed the tran-
scription of Cyp19 mRNA in human granu-
losa luteal cells (Rice et al. 2006). Although
isoflavones are generally weak aromatase
inhibitors, isoflavone mixtures displayed an
increased ability to inhibit aromatase activity
and transcription compared with any of the
isoﬂavones alone (Rice et al. 2006). A mixture
of genistein, daidzein, and biochanin A
almost completely eliminated transcription of
Cyp19 mRNA and significantly reduced
Cyp19 enzyme activity (Rice et al. 2006).
Resveratrol exerted both competitive and
noncompetitive inhibitory effects on aro-
matase activity in MCF7 cells stably trans-
fected with Cyp19, with an IC50 value of
approximately 25 μM (Wang et al. 2006).
Similarly, resveratrol suppressed transcription
of Cyp19 mRNA in SK-BR-3 breast cancer
cells. In contrast, genistein increased aro-
matase activity in H295R cells and in isolated
rat follicles (Myllymaki et al. 2005; Sanderson
et al. 2004). In addition to their interactions
with Cyp19, phytoestrogens have been shown
to inhibit HSD (Le Bail et al. 1998). For
example, genistein decreased HSD activity in
human placental microsomes, genital skin
fibroblasts, granulosa luteal cells, MCF7
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Figure 1. Chemical structures of E2 and the phytoestrogens resveratrol, genistein, quercetin, and daidzein.
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cells (Brooks and Thompson 2005; Evans
et al. 1995; Le Bail et al. 2000; Whitehead
et al. 2002). In MCF7 cells, genistein inhib-
ited HSD-catalyzed E2 production by 59%
(Brooks and Thompson 2005).
Given the carcinogenic properties of
endogenous estrogens, reducing their levels in
the body by inhibition of steroidogenic
enzymes such as Cyp19 and HSD would pro-
tect against breast cancer development
(Figure 2; Appendix 1). Thus, although stud-
ies have not detected consistent changes in
hormone levels after phytoestrogen intake and
the overall health effects of phytoestrogen
exposure remain unclear, these plant com-
pounds may decrease lifetime exposure to
estrogens, via two mechanisms, namely by
decreasing estrogen biosynthesis and by
increasing menstrual cycle length.
Phytoestrogens and the
Estrogen Receptors
The estrogen receptors ER-α and ER-β func-
tion as ligand-activated transcription factors
that initiate transcription by translocating to
the nucleus and binding to estrogen response
elements (ERE) in the promoter regions of tar-
get genes (McDonnell 2004). The actions of
ER-α and ER-β on gene transcription can be
opposite, depending on cell context (Koehler
et al. 2005). It is thought that ER-β may
impact estrogen action by directly modulating
gene transcription or by modulating ER-α
activity in tissues that express both ER sub-
types (Hall and McDonnell 1999). ER-β can
function as a transcriptional inhibitor or activa-
tor, depending on the agonist concentration,
such that different patterns of gene expression
are produced at different agonist concentra-
tions (Hall and McDonnell 1999). Studies in
MCF7 cells suggest that ER-β is not necessary
for proliferation and that ER-β opposes the
proliferative effects exerted by ER-α (Koehler
et al. 2005; Omoto et al. 2003; Strom et al.
2004). The interactions between the two main
ERs and their specific cofactors provide a
mechanistic basis for the tissue-selective actions
of estrogens (McDonnell 2004). The ratio of
ER-α to ER-β is a prognostic marker in breast
tumors, such that ER-β expression is indicative
of more benign tumors, whereas ER-α indi-
cates malignant, aggressive tumors (Balfe et al.
2004; Shaaban et al. 2003).
Many phytoestrogens, including resvera-
trol, genistein, daidzein, and quercetin, have
been shown to bind both ER-α and ER-β
and to induce the transcription of estrogen-
responsive target genes in a dose-dependent
manner (Bowers et al. 2000; Kuiper et al.
1997, 1998; Maggiolini et al. 2001).
However, phytoestrogens bind the ER with
much lower affinity compared with E2
(McCarty 2006; van der Woude et al. 2005).
The afﬁnity of quercetin for ER-α and ER-β
was shown to be 105- to 106-fold lower than
the afﬁnity of E2 for ER-α and ER-β (van der
Woude et al. 2005). Similarly, the afﬁnity of
daidzein for ER-α and ER-β was found to be
approximately 20,000- and 500-fold lower
than that of E2 (Lehmann et al. 2005).
Unlike E2, which binds both ER-α and
ER-β with similar afﬁnity, many phytoestro-
gens display a substantially higher afﬁnity for
ER-β. For example, the binding affinities of
genistein and daidzein for ER-β were shown to
be signiﬁcantly higher than for ER-α (Kuiper
et al. 1997, 1998; Lehmann et al. 2005).
Moreover, phytoestrogens induce the tran-
scription of estrogen-responsive target genes to
much greater levels when bound to ER-β than
when bound to ER-α. In MCF7 cells co-trans-
fected with either ER-α or ER-β, genistein was
shown to induce a 100-fold greater induction
of gene expression when bound to ER-β than
when bound to ER-α (Harris et al. 2005).
This result is in agreement with other evidence
that genistein preferentially binds ER-β and
induces greater DNA-binding and transcrip-
tional activity when bound to ER-β (An et al.
2001; Barkhem et al. 1998; Kostelac et al.
2003; Liu et al. 2003; Morito et al. 2001;
Mueller et al. 2004; Routledge et al. 2000).
Like genistein, resveratrol induced higher tran-
scriptional activity in estrogen-responsive genes
when bound to ER-β compared with ER-α
(Bowers et al. 2000).
Despite, the signiﬁcantly lower afﬁnity of
phytoestrogens for the ER compared with E2,
some phytoestrogens reportedly induce ER-
mediated gene transcription from both ER-α
and ER-β to higher levels than E2 (Harris et al.
2005; van der Woude et al. 2005). The
reported maximal inductions of gene transcrip-
tion from ER-α by genistein and quercetin
were 1.4- and 1.7-fold greater than those pro-
duced by E2 and 2.4- and 4.5-fold greater than
those produced by E2 for ER-β (van der
Woude et al. 2005). Similarly, the maximum
induction of ER-mediated genes by quercetin
for ER-α and ER-β were 1.7 and 4.5 times
greater than those reached by E2 (van der
Woude et al. 2005). In addition, the presence
of endogenous estrogens has been shown to
inﬂuence the effect of phytoestrogens on gene
transcription. For example, both genistein and
resveratrol were found to act synergistically
with E2 to activate ER-α– and ER-β–induced
gene transcription in MCF7 breast cancer cells
(Gehm et al. 1997; Harris et al. 2005).
Because phytoestrogens have signiﬁcantly
different afﬁnities for ER-α and ER-β, the net
effect of exposure to a particular phytoestro-
gen may depend on the distinctive patterns of
ER-α and ER-β expression in different cell
types (McDonnell 2004). The differential
affinities of phytoestrogens for ER-α and
ER-β suggest that physiologic concentrations
of phytoestrogens may be enough to activate
ER-β but not ER-α, implying that rather than
acting via the classical ER-α pathway, phyto-
estrogens may activate ER-β and induce its
antiproliferative effects (Figure 2; Appendix 1)
(McCarty 2006). Moreover, the presence of
type II sites in the breast and uterus adds
another dimension of complexity to phyto-
estrogen action. Type II sites, low-affinity
nuclear binding sites for E2 in the breast and
uterus, are suggested to be involved in regulat-
ing the growth and proliferation of both nor-
mal and malignant cells (Markaverich et al.
2001; Shoulars et al. 2002, 2005). Type II
sites have not been fully characterized,
although histone H4 binds type II ligands and
is thought to be the type II site (Markaverich
et al. 2001; Shoulars et al. 2002, 2005).
Phytoestrogens, speciﬁcally ﬂavonoids such as
quercetin, bind type II sites with high afﬁnity
and antagonize growth in a number of cell
types, suggesting another mechanism by
which phytoestrogens may modulate cell
proliferation (Griffiths and Smith 1972;
Mense et al.
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Figure 2. Summary of potential actions of phytoestrogens. Arrows indicate possible functions of phyto-
estrogens.
Phytoestrogen
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Stimulation of growth
of existing tumors
Induction of cell cycle
arrest and apoptosis
Increase in breast
tissue differentiation
Reduction in
estrogen biosynthesis
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estrogen metabolites
ER-β–mediated decrease in
cell growth and proliferation
ER-α–mediated stimulation in
cell growth and proliferationMarkaverich et al. 2001; Shoulars et al. 2002,
2005). Although many studies have been per-
formed, a more detailed understanding of how
phytoestrogens interact with the estrogen
receptor is critical to fully evaluate their toxi-
cologic and pharmacologic properties.
Phytoestrogens: Cellular
Growth and Proliferation
Evidence that phytoestrogens can activate the
estrogen receptor and may mimic endogenous
estrogens has raised concerns regarding their
effects on cell growth and proliferation. If
phytoestrogens, like estrogens, promote cell
growth, they may stimulate the expansion of
pre-existing tumors (Figure 2; Appendix 1).
However, the distinctive activities of the ER
isoforms as well as the differential afﬁnities of
low concentrations of phytoestrogens for
ER-β over ER-α suggest that the net effect of
phytoestrogen exposure on cell growth may
be quite different from those of estrogen on
the classic ER system (McCarty 2006).
Many phytoestrogens appear to have a
biphasic effect on cell proliferation, stimulat-
ing growth at low concentrations and sup-
pressing growth at high concentrations. At low
concentrations, resveratrol and quercetin dose
dependently promoted growth in ER-positive
MCF7 cells but inhibited proliferation and
induced cell death at high concentrations
(Ashby et al. 1999; Bowers et al. 2000; Gehm
et al. 1997; Lu and Serrero 1999; Maggiolini
et al. 2001; Schmitt et al. 2002; van der
Woude et al. 2005). Similarly, genistein was
shown to increase growth in estrogen-sensitive
cells at low concentrations but decreased cell
growth, suppressed DNA synthesis, and
induced cell death at high concentrations
(Maggiolini et al. 2001; Seo et al. 2006). A
recent study revealed that the proliferation
observed in daidzein-treated MCF7 cells was
blocked by the pure antiestrogen ICI 182,780,
indicating that the stimulatory effect exerted
by daidzein was ER-mediated (Ju et al.
2006b). While phytoestrogens promote
cell growth in ER-positive cells, evidence
suggests that ER-negative cells may have dif-
ferent responses to phytoestrogen exposure.
In the ER-negative breast cancer cell line
MDA-MB-468, resveratrol inhibited cell pro-
liferation at all concentrations lower than
10 nM (Ashby et al. 1999; Bowers et al. 2000;
Gehm et al. 1997; Lu and Serrero 1999;
Schmitt et al. 2002). Similarly, low concentra-
tions of quercetin and genistein reduced pro-
liferation or had no stimulatory effect on
ER-negative MDA-MB-231, HCC-38, and
HeLa cells (Balabhadrapathruni et al. 2000;
van der Woude et al. 2005).
The effects of phytoestrogens on the
growth and proliferation of tumor cells have
also been evaluated in vivo, using animal
models of breast cancer and breast cancer cell
xenografts. Genistein and soy protein stimu-
lated the growth of MCF7 breast cancer cell
xenografts implanted in mice (Allred et al.
2001; Hsieh et al. 1998). Similarly, genistein,
in the presence of low levels of E2, acted in an
additive manner to stimulate the growth of
MCF7 tumors in mice (Ju et al. 2006a).
However, other studies have generated con-
flicting results. Genistein inhibited the
growth of both ER-positive and ER-negative
breast cancer xenografts and induced apopto-
sis in tumor cells (Shao et al. 1998). Similarly,
resveratrol reduced tumor growth and
increased apoptosis in ER-α–negative/
ER-β–positive MDA-MB-231 tumor xeno-
grafts (Garvin et al. 2006).
The effects of phytoestrogens on cell
growth and proliferation may be explained by
their ability to alter the expression of a num-
ber of proteins that control cell cycle and
induce cell cycle arrest and apoptosis. In
MCF7 and MDA-MB-231 cells, resveratrol
caused cells to accumulate in the S-phase and
down-regulated Bcl-2, resulting in apoptosis
(Pozo-Guisado et al. 2002, 2005). The effect
of resveratrol on the cell cycle is suggested to
be mediated by its opposing effects on cell
cycle regulators. Resveratrol increased the
expression and activity of positive G1/S and
G2/M cell cycle regulators, while simultane-
ously increasing protein levels of p21, p53,
and p27 (Pozo-Guisado et al. 2002).
Similarly, both genistein and quercetin caused
G2/M arrest and apoptosis in MDA-MB-231
cells (Balabhadrapathruni et al. 2000).
Increased cyclin B1 protein levels were
observed in MDA-MB-231 cells following
exposure to low doses of genistein, but
MDA-MB-231 cells exposed to high concen-
trations of genistein displayed decreased levels
of cyclin B1 and phosphorylated Cdc2
(Balabhadrapathruni et al. 2000). Further,
daidzein was shown to alter cell cycle distribu-
tion and induce apoptosis in HeLa cells (Guo
et al. 2004).
To resolve the dilemma regarding the
potential beneficial or harmful effects of
phytoestrogens in breast cancer development,
numerous studies have attempted to charac-
terize the estrogenic and growth-stimulatory
actions of phytoestrogens. Most of these stud-
ies have been carried out in transformed
breast cancer cell lines. To further our under-
standing of the proliferative effects of phyto-
estrogens, studies need to be performed in
both nontumorigenic and tumorigenic breast
cells with varying ER status and in environ-
ments with varying estrogen concentrations.
Phytoestrogens and Tumor
Development
Various phytoestrogens have been evaluated
for their ability to prevent chemically induced
mammary carcinogenesis. Resveratrol blocked
the formation of preneoplastic lesions, sup-
pressed mammary carcinogenesis, reduced
tumor incidence, and increased tumor latency
in Sprague-Dawley rats treated with dimethyl-
benz[a]anthracene (DMBA) (Whitsett et al.
2006). Both resveratrol and quercetin
have been shown to inhibit N-methyl-
N-nitrosourea (NMU) and DMBA-induced
mammary carcinogenesis in rats (Banerjee
et al. 2002; Bhat et al. 2001; Verma et al.
1988). Resveratrol decreased NMU- and
DMBA-induced tumor incidence and multi-
plicity by 50% in Sprague-Dawley rats
(Banerjee et al. 2002; Bhat et al. 2001).
Daidzein inhibited DMBA-induced mam-
mary tumors in rats and signiﬁcantly increased
tumor latency in mouse mammary tumor
virus-neu mice (Constantinou et al. 2001; Jin
and MacDonald 2002). Similarly, several
studies have demonstrated that rats exposed to
genistein early in life have a decreased inci-
dence of DMBA-induced mammary tumors
in adulthood (Fritz et al. 1998; Hilakivi-
Clarke et al. 1999; Lamartiniere et al. 1998;
Murrill et al. 1996). However, others have
reported that genistein increased tumor cross-
sectional area, increased tumor multiplicity,
elevated the percentage of proliferative cells in
tumors and increased the weight of estrogen-
dependent mammary adenocarcinomas in rat
models of mammary cancer (Allred et al.
2004; Kijkuokool et al. 2006).
In addition, phytoestrogen exposure has
been shown to alter breast development
(Figure 2; Appendix 1). Resveratrol-exposed
female rats displayed more differentiated lobu-
lar structures and decreased proliferation in
the mammary terminal ductal structures, mak-
ing them less vulnerable to damage by carcino-
gens (Whitsett et al. 2006). Exposure to
genistein during breast development altered
breast morphology and resulted in decreased
terminal ductal formation (Hilakivi-Clarke
et al. 1999). However, the relationship
between phytoestrogens and tumor develop-
ment does not always appear to be protective
and may rely on age at exposure and the hor-
monal environment. Quercetin potentiated
the severity of E2-induced kidney tumorigene-
sis in male Syrian hamsters, and prepubescent
rats treated with resveratrol showed accelerated
NMU-induced mammary carcinogenesis and
elevated tumor incidence and multiplicity
(Sato et al. 2003; Zhu and Liehr 1994).
Taken together, these studies indicate that
certain phytoestrogens might reduce the risk
of chemically induced mammary cancers in
animal models, particularly if exposure is early
in life. However, very few studies have
focused on the effect of phytoestrogens on
estrogen-induced breast cancers, which would
be the most relevant model for gaining insight
into the relationship between phytoestrogens
and human mammary carcinogenesis.
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Phytoestrogens and Signaling
Pathways
The inﬂuence of ERs on the transcription of
estrogen-sensitive genes is not limited to ERE
binding. An increasing body of evidence sug-
gests that both ER-α and ER-β participate in
some of the signaling cascades responsible for
controlling gene expression, cell cycle, cell pro-
liferation and apoptosis (Levin 1999; Marquez
and Pietras 2001; Pietras et al. 2005a, 2005b).
Several phytoestrogens have been shown to
modulate the activity of ER-associated signaling
cascades and transcription factors. In human
breast cells, resveratrol inhibited ER-α–associ-
ated PI3K activity, thereby exerting an
inhibitory effect on cell proliferation and sur-
vival (Pozo-Guisado et al. 2005). Genistein and
daidzein activated Akt in the ER-α–positive
T47D breast cancer cell line, whereas resvera-
trol inhibited Akt phosphorylation (Brownson
et al. 2002). In the ER-α–negative MDA-
MB-231 breast cancer cell line, resveratrol and
daidzein activated Akt but genistein did not
(Brownson et al. 2002). Resveratrol has been
shown to modulate nuclear factor kappa B
(NFκB) and AP-1 activation in various cancer
cell lines, leading to the speculation that NFκB
and AP-1 are potential targets of resveratrol
(Banerjee et al. 2002; Kundu and Surh 2004).
In MCF7 cells and chemically induced rat
mammary tumors, resveratrol inhibited the
DNA-binding activity of NFκB (Banerjee et al.
2002). Resveratrol inhibited extracellular sig-
nal–regulated kinase (ERK) and p38 mitogen-
activated protein kinase (MAPK) activation in
mouse skin cells, suggesting that resveratrol
may inhibit the activation of NFκB and AP-1
at the level of their upstream kinases, ERK and
p38 MAPK (Yu et al. 2001). Similarly, genis-
tein blocked the NFκB signaling pathway via
an Akt-dependent mechanism in both
MDA-MB-231 breast cancer cells and PC3
prostate cancer cells (Gong et al. 2003; Li and
Sarkar 2002). Genistein and daidzein sup-
pressed NFκB activation in TNFα-stimulated
mouse fibroblasts and in ER-negative breast
cancer cells by a mechanism that involved abro-
gation of MEK1 and ERK activity (Vanden
Berghe et al. 2006). Treatment of mouse
ﬁbroblasts with the antiestrogen ICI 182780
failed to reverse the effects of daidzein and
genistein on NFκB-dependent gene expression,
indicating that suppression of NFκB is inde-
pendent of the estrogenic activity of phyto-
estrogens (Vanden Berghe et al. 2006).
Recently, microarray technologies have
been exploited in order to clarify the estro-
genic effects of phytoestrogen exposure on
gene expression and signaling pathways (Chen
et al. 2003; Ise et al. 2005; Naciff et al. 2002).
One such study compared the effects of genis-
tein and E2 exposure on the reproductive tis-
sues of the developing rat fetus, speciﬁcally the
ovaries and uterus (Naciff et al. 2002).
Expression patterns of genes whose products
were involved in cell growth, differentiation,
stress response and apoptosis were modulated
by both genistein and E2. However, genistein
exposure altered the expression patterns of a
number of genes in a manner distinct from E2
(Naciff et al. 2002). Genistein increased the
expression of MAPK and topisomerase II,
whereas the expression of phospholipase A2
was down-regulated. In contrast, the expres-
sion of these genes was not affected by E2
exposure (Naciff et al. 2002). Another study,
in which MCF7 breast cancer cells were
treated with genistein, showed down-regula-
tion of genes whose products are associated
with cell growth, DNA replication, and
growth factor response (Chen et al. 2003). In
a separate study, gene expression profiles in
MCF7 breast cancer cells were evaluated after
exposure to either phytoestrogens or E2 (Ise
et al. 2005). The authors reported similar but
distinct expression patterns for each of the
phytoestrogens tested and analyses revealed
that the phytoestrogen exposure induced
expression profiles with differing degrees of
similarity to E2 (Ise et al. 2005).
Phytoestrogens and Estrogen-
Metabolizing Enzymes
Once ingested, phytoestrogens interact with
many of the same enzymes as endogenous
estrogens and have been shown to interfere
with the process of estrogen metabolism
(Moon et al. 2006). Several phytoestrogens
are known to modify the CYP450 enzyme
system by either inducing or suppressing the
transcription of CYP450 enzymes or by
inhibiting or enhancing enzyme activity
(Figure 2; Appendix 1) (Moon et al. 2006).
The expression of two main estrogen-metabo-
lizing enzymes, Cyp1A1 and Cyp1B1, is
under the control of the aryl hydrocarbon
receptor (AhR), a ligand-activated transcrip-
tion factor, which binds a specific DNA
sequence designated xenobiotic response ele-
ment (XRE) in the promoter regions of its
target genes (Nebert et al. 2000).
Resveratrol, genistein and quercetin have
been shown to decrease both xenobiotic-
induced transcription and activity of Cyp1A1
and Cyp1B1 in numerous cell types (Berge
et al. 2004; Chan et al. 2003; Chang et al.
2001; Chun et al. 1999; Ciolino and Yeh
1999; Han et al. 2006; Lee and Safe 2001;
Ramadass et al. 2003; Roberts et al. 2004;
Shertzer et al. 1999). Resveratrol is an AhR
antagonist and is suggested to exert its
inhibitory effects on Cyp1A1 and Cyp1B1
expression either by suppressing AhR DNA-
binding activity or by preventing the inter-
action between AhR and the transcriptional
complex, thereby blocking induction of AhR-
mediated genes (Casper et al. 1999; Chen
et al. 2004). Similarly, genistein and quercetin
are suspected to decrease xenobiotic-induced
Cyp1A1 and Cyp1B1 mRNA expression by
interfering with activation of the XRE by AhR
(Chan et al. 2003; Ramadass et al. 2003). In
contrast, quercetin has been shown to both
increase and decrease Cyp1A1 enzyme activity
(Ciolino et al. 1999; Ramadass et al. 2003).
Not only do phytoestrogens interact with
the Cyp450 enzyme system, quercetin inhibits
the O-methylation of endogenous estrogens by
catechol-O-methyltransferase (COMT) by a
combination of three mechanisms—direct
competition for COMT, noncompetitive inhi-
bition via an increase in S-adenosyl-L-homo-
cysteine (SAH) concentrations and by reducing
the availability of the methyl donor S-adenosyl
methionine (SAM) (Zhu 2002). Various stud-
ies have established that quercetin is an excel-
lent substrate for COMT, having a metabolic
rate up to 30 times higher than catechol estro-
gens (Zhu 2002). In Syrian hamsters treated
with E2, quercetin increased the concentrations
of 2-hydroxyestradiol (2-OHE2) and
4-hydroxyestradiol (4-OHE2) in kidney and
decreased urinary excretion of 2-methoxyestra-
diol (2-MeOHE2) and 4-methoxyestradiol
(4-MeOHE2) (Zhu and Liehr 1996).
The evidence that phytoestrogens alter
estrogen-metabolizing enzymes is not limited
to in vitro data. Data from nonhuman pri-
mate studies suggest that exposure to phyto-
estrogens alters the pathways of estrogen
metabolism by Cyp1A1 and Cyp1B1 in vivo
such that it is shifted toward the production
of fewer genotoxic metabolites (Lu et al.
2000b; Wood et al. 2006). However, inhibi-
tion of COMT by phytoestrogens would not
only lead to elevated tissue levels of the pro-
carcinogenic estrogen metabolite 4-OHE2,
but also to decreased levels of the anti-
carcinogenic estrogen metabolite 2-MeOHE2
(Badawi et al. 2001; Zhu 2002). Thus, it is
Appendix 1. Overview of
possible mechanisms of
phytoestrogen action.
Putative anticancer actions
• Inhibition of HSD and Cyp19 to decrease
endogenous estrogen levels
• Modulation of Cyp450s to reduce ratio
of genotoxic estrogens to total estrogens
• Activation of ER-β to exert antiprolifera-
tive and prodifferentiative effects
• Reduction of mammary sensitivity to car-
cinogens by altering breast development/
morphology
Putative procancer actions
• Stimulation of growth and proliferation of
breast epithelial cells via ER-α activation
• Stimulation of growth and proliferation
of existing tumors via ER-α activationEnvironmental Health Perspectives • VOLUME 116 | NUMBER 4 | April 2008 431
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important for future studies to further eluci-
date the abilities of phytoestrogens to alter the
metabolism of endogenous estrogens, as these
processes are critical to understanding the
relationship between phytoestrogens and
breast cancer development.
Conclusion
Epidemiologic evidence has been inconclusive
regarding the effects of phytoestrogen con-
sumption on breast cancer risk. Nevertheless,
extensive research has been performed to pro-
vide a detailed description of the possible
mechanisms of action of phytoestrogens.
Taken together, the research on phytoestro-
gens, particularly studies relevant to genistein,
daidzein, resveratrol, and quercetin, suggests
that these compounds do not act by a single
mechanism to achieve their effects. Instead,
these plant substances exert their effects by
way of various mechanisms, including effects
on estrogen-metabolizing enzymes, cell cycle,
cell differentiation, proliferation, apoptosis,
the inflammatory response and various cell
signaling pathways.
While there is some evidence supporting a
chemoprotective role for phytoestrogens in
breast cancer, there is also evidence suggesting
the possible adverse effects of phytoestrogen
consumption. More research is needed in
order to fully evaluate the activities of phyto-
estrogens and the biological relevance of
experimental findings. Future studies may
focus elucidating the mechanisms underlying
phytoestrogen action and to characterizing
the actions of phytoestrogens in different
hormonal environments.
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